Screener
Cingulate
CINGCingulate Inc. is a biopharmaceutical company focused on developing next-generation pharmaceutical products using its proprietary Precision Timed Release (PTR) drug delivery platform.
$64.71M+204%
Earnings
Next report
Date not yet announcedCompetitors
By market cap
By revenue growth
Profile
Cingulate Inc. is a biopharmaceutical company focused on developing next-generation pharmaceutical products using its proprietary Precision Timed Release (PTR) drug delivery platform. The company targets conditions requiring complex daily dosing regimens, such as ADHD and anxiety, by creating once-daily, multi-dose tablets designed to improve patient compliance and treatment outcomes.
Competitive position
Cingulate is a clinical-stage developer seeking to disrupt the ADHD market by addressing the 'booster dose' unmet need through its proprietary erosion barrier layer technology.
GeographiesUnited States, Europe
Customer segmentsPatients, Healthcare Providers, Payers
Business modelDrug Development, IP Licensing
SuppliersActive Pharmaceutical Ingredient (API) suppliers, Contract Development and Manufacturing Organizations (CDMOs), Clinical Research Organizations (CROs)
CustomersWholesale distributors, Pharmacies, Hospitals, Healthcare providers
CountryUnited States of America
Listed2021
Employees13.0
CEOShane J. Schaffer
SectorHealthcare
IndustryBiotechnology
Websitecingulate.com
FilingsSEC EDGAR
FAQ
- What is Cingulate's market cap?
- Cingulate (CING) has a market capitalization of $64.7M and trades on NASDAQ.
- Who are Cingulate's competitors?
- Cingulate's key competitors include Aytu BioPharma, Inc., Janssen Pharmaceuticals, NRX Pharmaceuticals, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does Cingulate partner with?
- Cingulate's notable partners include Indegene, Inc., IQVIA Inc., CoreRx, Inc., and others.
- What subsidiaries does Cingulate have?
- Cingulate's subsidiaries include Cingulate Therapeutics LLC.
- Where is Cingulate headquartered?
- Cingulate is headquartered in United States of America and employs approximately 13 people. It has been publicly traded since 2021.